Published: March 2016 | Report Code: LS10628 | Available Format: PDF | Pages: 83
Chapter 1. Research Scope and Methodology
1.1 Market Definition
1.2 Market Scope
1.2.1 Global AMD market breakdown by type
1.2.2 Global AMD market breakdown by drug
1.2.3 Global AMD market breakdown by geography
1.3 Research Methodology and Sources
Chapter 2. Executive Summary
2.1 Key Findings
2.2 Research Summary
Chapter 3. Market Outlook
3.1 Introduction
3.1.1 Diagnosis of AMD
3.1.2 Stages of AMD
3.1.3 Treatment of AMD
3.1.4 Various drugs for the treatment of AMD
3.1.4.1 Lucentis
3.1.4.2 Eylea
3.1.4.3 Avastin
3.1.4.4 Visudyne
3.2 Trends in the Market
3.2.1 Increasing awareness of AMD
3.3 Factors Driving Growth of the Market and its Impact on Market Forecast
3.3.1 Growing geriatric population
3.3.2 Increasing prevalence of AMD
3.3.3 Increasing prevalence of lifestyle associated diseases
3.3.4 Increasing pipeline drugs for AMD
3.3.5 Increasing healthcare cost
3.3.6 Impact analysis of drivers on market forecast
3.4 Factors Hindering the Growth of the Market and its Impact on Market Forecast
3.4.1 Increase in off label use
3.4.2 Stringent regulatory requirements
3.4.3 Impact analysis of restraints on market forecast
Chapter 4. Drug Approval Process in the U.S. and EU
4.1 Drug approval process in the U.S.
4.2 Drug approval process in the EU
Chapter 5. Global Age-related Macular Degeneration Market Size and Forecast (2012 – 2022)
5.1 Global AMD Market, by Type
5.2 Global AMD Market, by Drug
5.3 Global AMD Market, by Region
Chapter 6. Global Age-related Macular Degeneration Market, by Type
6.1 Dry AMD Market
6.2 Wet AMD Market
Chapter 7. Global Age-related Macular Degeneration Market, by Geography
7.1 North America AMD Market
7.1.1 North America AMD market, by type
7.1.2 North America AMD market, by country
7.2 Europe AMD Market
7.2.1 Europe AMD market, by type
7.2.2 Europe AMD market, by country
7.3 Asia-Pacific AMD Market
7.3.1 Asia-Pacific AMD market, by type
7.3.2 Asia-Pacific AMD market, by country
7.4 Rest of the World (RoW) AMD Market
7.4.1 RoW AMD market, by type
Chapter 8. Competitive Positioning Analysis
8.1 Porter’s Five Forces of Competitive Position Analysis
8.1.1 Bargaining power of buyers
8.1.2 Bargaining power of suppliers
8.1.3 Threat of new entrants
8.1.4 Intensity of rivalry
8.1.5 Threat of substitutes
8.2 Pipeline Analysis of AMD drugs
Chapter 9. Company Profiles and Strategic Developments
9.1 Key Company Profiles
9.1.1 Novartis AG
9.1.1.1 Business overview
9.1.1.2 Product and service offerings
9.1.2 F. Hoffmann-La Roche Ltd
9.1.2.1 Business overview
9.1.2.2 Product and service offerings
9.1.3 Bayer AG.
9.1.3.1 Business overview
9.1.3.2 Product and service offerings
9.1.4 Regeneron Pharmaceutical, Inc.
9.1.4.1 Business overview
9.1.4.2 Product and service offerings
9.1.5 Acucela
9.1.5.1 Business overview
9.1.5.2 Product and service offerings
9.1.6 Ophthotech Corporation
9.1.6.1 Business overview
9.1.6.2 Product and service offerings
9.1.7 Neurotech Pharmaceuticals, Inc.
9.1.7.1 Business overview
9.1.7.2 Product and service offerings
9.1.8 GlaxoSmithKline plc
9.1.8.1 Business overview
9.1.8.2 Product and service offerings
9.1.9 StemCells Inc.
9.1.9.1 Business overview
9.1.9.2 Product and service offerings
9.1.10 Alimera Sciences, Inc.
9.1.10.1 Business overview
9.1.10.2 Product and service offerings
9.2 Strategic Developments in the AMD Market
9.2.1 Collaborations/ partnerships
9.2.2 Product approval/launch
9.2.3 Merger and acquisition
9.2.4 Other developments
Chapter 10. Appendix
10.1 List of Abbreviations
LIST OF TABLES
TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION
TABLE 2 GLOBAL AMD MARKET SNAPSHOT
TABLE 3 SOME OF THE PIPELINE DRUGS OF AMD IN MAJOR COMPANIES
TABLE 4 HEALTHCARE EXPENDITURE AS % OF GDP
TABLE 5 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 6 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 7 GLOBAL AMD MARKET, BY TYPE, $M (2012 – 2015)
TABLE 8 GLOBAL AMD MARKET, BY TYPE, $M (2016 – 2022)
TABLE 9 GLOBAL AMD MARKET, BY DRUG, $M (2012 – 2015)
TABLE 10 GLOBAL AMD MARKET, BY DRUG, $M (2016 – 2022)
TABLE 11 GLOBAL AMD MARKET, BY REGION, $M (2012 – 2015)
TABLE 12 GLOBAL AMD MARKET, BY REGION, $M (2016 – 2022)
TABLE 13 GLOBAL DRY AMD MARKET, BY REGION, $M (2012 – 2015)
TABLE 14 GLOBAL DRY AMD MARKET, BY REGION, $M (2016 – 2022)
TABLE 15 GLOBAL WET AMD MARKET, BY REGION, $M (2012 – 2015)
TABLE 16 GLOBAL WET AMD MARKET, BY REGION, $M (2016 – 2022)
TABLE 17 NORTH AMERICA AMD MARKET, BY TYPE, $M (2012 – 2015)
TABLE 18 NORTH AMERICA AMD MARKET, BY TYPE, $M (2016 – 2022)
TABLE 19 NORTH AMERICA AMD MARKET, BY COUNTRY, $M (2012 – 2015)
TABLE 20 NORTH AMERICA AMD MARKET, BY COUNTRY, $M (2016 – 2022)
TABLE 21 EUROPE AMD MARKET, BY TYPE, $M (2012 – 2015)
TABLE 22 EUROPE AMD MARKET, BY TYPE, $M (2016 – 2022)
TABLE 23 EUROPE AMD MARKET, BY COUNTRY, $M (2012 – 2015)
TABLE 24 EUROPE AMD MARKET, BY COUNTRY, $M (2016 – 2022)
TABLE 25 ASIA-PACIFIC AMD MARKET, BY TYPE, $M (2012 – 2015)
TABLE 26 ASIA-PACIFIC AMD MARKET, BY TYPE, $M (2016 – 2022)
TABLE 27 ASIA-PACIFIC AMD MARKET, BY COUNTRY, $M (2012 – 2015)
TABLE 28 ASIA-PACIFIC AMD MARKET, BY COUNTRY, $M (2016 – 2022)
TABLE 29 ROW AMD MARKET, BY TYPE, $M (2012 – 2015)
TABLE 30 ROW AMD MARKET, BY TYPE, $M (2016 – 2022)
TABLE 31 NOVARTIS AG – KEY FACTS
TABLE 32 F. HOFFMANN-LA ROCHE LTD – KEY FACTS
TABLE 33 BAYER AG – KEY FACTS
TABLE 34 REGENERON PHARMECEUTICALS, INC. – KEY FACTS
TABLE 35 ACUCELA– KEY FACTS
TABLE 36 OPHTHOTECH CORPORATION– KEY FACTS
TABLE 37 NEUROTECH PHARMACEUTICALS, INC.– KEY FACTS
TABLE 38 GLAXOSMITHKLINE PLC – KEY FACTS
TABLE 39 STEMCELLS INC.– KEY FACTS
TABLE 40 ALIMERA SCIENCES, INC. KEY FACT
LIST OF FIGURES
FIG 1 MARKET SCOPE FOR GLOBAL AMD MARKET
FIG 2 RESEARCH METHODOLOGY FOR GLOBAL AMD MARKET
FIG 3 ANATOMICAL STRUCTURE OF AN EYE
FIG 4 CROSS SECTION OF A MACULA
FIG 5 AMSLER GRID TEST
FIG 6 OPTICAL COHERENCE TOMOGRAPHY OF AN EYE
FIG 7 INNOVATION OF WET AMD TREATMENT
FIG 8 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION, IN MAJOR COUNTRIES
FIG 9 PREVALENCE OF OVERWEIGHT MEN AGED 30 AND ABOVE, IN % (2005 AND 2015)
FIG 10 PREVALENCE OF OVERWEIGHT WOMEN AGED 30 AND ABOVE, IN % (2005 AND 2015)
FIG 11 BASIC DRUG DEVELOPMENT PROCEDURE
FIG 12 GLOBAL AMD MARKET SIZE, $M (2012 – 2022)
FIG 13 GLOBAL AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)
FIG 14 GLOBAL AMD MARKET SIZE, BY DRUG, $M (2012 – 2022)
FIG 15 GLOBAL AMD MARKET SHARE, BY DRUG (2015 AND 2022)
FIG 16 GLOBAL AMD MARKET SIZE, BY REGION, $M (2012 – 2022)
FIG 17 GLOBAL AMD MARKET SHARE, BY REGION (2015 AND 2022)
FIG 18 GLOBAL DRY AMD MARKET SIZE, BY REGION, $M (2012 – 2022)
FIG 19 GLOBAL WET AMD MARKET SIZE, BY REGION, $M (2012 – 2022)
FIG 20 GLOBAL AMD MARKET SIZE, BY GEOGRAPHY (2022)
FIG 21 NORTH AMERICA AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)
FIG 22 NORTH AMERICA AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)
FIG 23 EUROPE AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)
FIG 24 EUROPE AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)
FIG 25 ASIA-PACIFIC AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)
FIG 26 ASIA-PACIFIC AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)
FIG 27 ROW AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)
FIG 28 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS
FIG 29 PIPELINE ANALYSIS OF AMD DRUGS (2015)
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws